39 related articles for article (PubMed ID: 2232889)
1. Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.
Rudd SG; Tsesmetzis N; Sanjiv K; Paulin CB; Sandhow L; Kutzner J; Hed Myrberg I; Bunten SS; Axelsson H; Zhang SM; Rasti A; Mäkelä P; Coggins SA; Tao S; Suman S; Branca RM; Mermelekas G; Wiita E; Lee S; Walfridsson J; Schinazi RF; Kim B; Lehtiö J; Rassidakis GZ; Pokrovskaja Tamm K; Warpman-Berglund U; Heyman M; Grandér D; Lehmann S; Lundbäck T; Qian H; Henter JI; Schaller T; Helleday T; Herold N
EMBO Mol Med; 2020 Mar; 12(3):e10419. PubMed ID: 31950591
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.
Elsayed AH; Cao X; Crews KR; Gandhi V; Plunkett W; Rubnitz JE; Ribeiro RC; Pounds SB; Lamba JK
Pharmacogenomics; 2018 Sep; 19(14):1101-1110. PubMed ID: 30088438
[TBL] [Abstract][Full Text] [Related]
3. SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia.
Marrero RJ; Cao X; Wu H; Elsayed AH; Klco JM; Ribeiro RC; Rubnitz JE; Ma X; Meshinchi S; Aplenc R; Kolb EA; Ries RE; Alonzo TA; Pounds SB; Lamba JK
Blood Adv; 2023 Jun; 7(11):2538-2550. PubMed ID: 36689724
[TBL] [Abstract][Full Text] [Related]
4. A new technique for the analysis of metabolic pathways of cytidine analogues and cytidine deaminase activities in cells.
Ligasová A; Piskláková B; Friedecký D; Koberna K
Sci Rep; 2023 Nov; 13(1):20530. PubMed ID: 37993628
[TBL] [Abstract][Full Text] [Related]
5. Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.
Di Francia R; Crisci S; De Monaco A; Cafiero C; Re A; Iaccarino G; De Filippi R; Frigeri F; Corazzelli G; Micera A; Pinto A
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33669053
[TBL] [Abstract][Full Text] [Related]
6. Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.
Tsesmetzis N; Paulin CBJ; Rudd SG; Herold N
Cancers (Basel); 2018 Jul; 10(7):. PubMed ID: 30041457
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
8. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
Cao X; Mitra AK; Pounds S; Crews KR; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
Pharmacogenomics; 2013 Sep; 14(12):1449-66. PubMed ID: 24024897
[TBL] [Abstract][Full Text] [Related]
9. The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.
Emadi A; Karp JE
Pharmacogenomics; 2012 Aug; 13(11):1257-69. PubMed ID: 22920396
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Gandhi V; Xu YZ; Estey E
Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
[TBL] [Abstract][Full Text] [Related]
11. Genetic factors influencing cytarabine therapy.
Lamba JK
Pharmacogenomics; 2009 Oct; 10(10):1657-74. PubMed ID: 19842938
[TBL] [Abstract][Full Text] [Related]
12. Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Gandhi V; Estey E; Keating MJ; Plunkett W
Leuk Lymphoma; 1993; 10 Suppl():109-14. PubMed ID: 8481660
[TBL] [Abstract][Full Text] [Related]
13. Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo.
Chiba P; Tihan T; Szekeres T; Salamon J; Kraupp M; Eher R; Köller U; Knapp W
Leukemia; 1990 Nov; 4(11):761-5. PubMed ID: 2232889
[TBL] [Abstract][Full Text] [Related]
14. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
[TBL] [Abstract][Full Text] [Related]
15. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
